When services can be administered in various settings, the Company reserves the right to reimburse only those services that are furnished in the most appropriate and cost-effective setting that is appropriate to the member’s medical needs and condition. This decision is based on the member’s current medical condition and any required monitoring or additional services that may coincide with the delivery of this service.
This Medical Policy Bulletin document describes the status of medical technology at the time the document was developed. Since that time, new technology may have emerged or new medical literature may have been published. This Medical Policy Bulletin will be reviewed regularly and be updated as scientific and medical literature becomes available. For more information on how Medical Policy Bulletins are developed, go to the About This Site section of this Medical Policy Web site.
American College of Obstetricians and Gynecologists (ACOG). Innovative practice: Ethical guidelines. Obstet Gynceol. 2006:108(6):1589-1895.
American College of Obstetricians and Gynecologists; Committee on Practice Bulletins—Obstetrics. ACOG practice bulletin no. 159: Management of preterm labor. Obstet Gynecol. 2016;127(1): e29–38. (Replaced by Practice Bulletin 171).
American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 130: Prediction and Prevention of Preterm Birth. Obstet Gynecol. 2012;120:964–73. Reaffirmed 2016.
Blondel B, Breart G, Berthoux Y, et al. Home uterine activity monitoring in France: a randomized, controlled trial. Am J Obstet Gynecol. 1992; 167(2):424-9.
Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Home uterine activity monitoring for secondary prevention of preterm birth. TEC Assessments 1996; Volume 11, Tab 15.
Brown HL, Britton KA, Brizendine EJ, et al. A randomized comparison of home uterine activity monitoring in the outpatient management of women treated for preterm labor. Am J Obstet Gynecol. 1999;180(4):798-805.
Collaborative Home Uterine Monitoring Study (CHUMS) Group. A multicenter randomized controlled trial of home uterine monitoring: active versus sham device. Am J Obstet Gynecol. 1995;173(4):1120-7.
Committee on Understanding Premature Birth and Assuring Healthy Outcomes. 2007. Preterm birth: Causes, consequences, and prevention. Section III: Diagnosis and treatment of preterm labor, Chapter Nine: Diagnosis and treatment of conditions leading to spontaneous preterm birth. Also available online at: http://books.nap.edu/openbook.php?record_id=11622&page=R1. Accessed November 29, 2017.
Dyson DC, Danbe KH, Bamber JA, et al. Monitoring women at risk for preterm labor. N Engl J Med. 1998;338(1):15-9.
Honest H, Forbes CA, Duree KH, et al. Screening to prevent spontaneous preterm birth: systematic reviews of accuracy and effectiveness literature with economic modeling. Health Technol Assess. 2009;13 (43):1-627.
Iams JD, Johnson FF, O’Shaughnessy RW. Ambulatory uterine activity monitoring in the post-hospital care of patients with preterm labor. Am J Perinatol. 1990;7(2):170-3.
Iams JD, Newman RB, Thom EA, et al. Frequency of uterine contractions and the risk of spontaneous preterm delivery. N Engl J Med. 2002 Jan 24;346(4):250-5.
Nagey DA, Bailey-Jones C, Herman AA. Randomized comparison of home uterine activity monitoring and routine care in patients discharged after treatment for preterm labor. Obstet Gynecol. 1993; 82(3):319-23.
National Institute of Child Health and Human Development. Home uterine monitors not useful for predicting premature birth. January 23, 2002. Available online at: http://www.nichd.nih.gov/news/releases/uterine.cfm. Last accessed November 29, 2017.
Rittenberg C, Newman RB, Istwan NB, et al. Preterm birth prevention by 17 alpha-hydroxyprogesterone caproate vs. daily nursing surveillance. J Reprod Med. 2009;54(2):47-52.
Urquhart C, Currell R, Harlow F, et al. Home uterine monitoring for detecting preterm labour. Cochrane Database Syst Rev. 2012;5:CD006172.
Urquhart C, Currell R, Harlow F, et al. Home uterine monitoring for detecting preterm labour. Cochrane Database Syst Rev. 2017;2:CD006172.
Urquhart C, Currell R, Harlow F, et al. Home uterine monitoring for detecting preterm labour. Cochrane Database Syst Rev. 2015; 1:CD006172.
US Food and Drug Administration (FDA). Devices@FDA. 884.2730 Home uterine activity monitor. [FDA Web site]. Original: 03/09/01. (Revised: 04/01/17). Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=884.2730. Accessed November 29, 2017.
US Food and Drug Administration (FDA). Federal Register. Obstetrics and gynecology devices; reclassification of home uterine activity monitor. Docket No. 97P-0350. [FDA Web site]. 07/30/99. Available at: http://www.fda.gov/ohrms/dockets/98fr/073099b.txt. Accessed November 29, 2017.
US Food and Drug Administration (FDA). Final Guidance for Industry and FDA Reviewers: Class II Special Controls Guidance for Home Uterine Activity Monitors. Original: 03/9/01 (Page last updated 07/13/2015). Available at: http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm237292.htm. Accessed November 29, 2017.